Full-Time

Clinical Trial Assistant II

Clinical Operations Process and Systems

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$80k - $100kAnnually

Entry

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • RN or bachelor’s degree in biological sciences or health-related field desired.
  • 0-1 years (CTA I)/1-3 years (CTA II) relevant experience in the pharmaceutical or biotech industry, preferably in Clinical Operations or Clinical Research-related experience.
  • Has knowledge of Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guideline
  • Thrives in a collaborative team setting and is driven by a desire to deploy innovative approaches and technologies in a high-energy environment.
  • Excellent written and verbal communication and interpersonal skills.
  • Demonstrate proficiency in Microsoft Office Suite (Outlook, MS Word, Excel, PowerPoint); MS Project and/or Smartsheet a plus.
  • Travel may be required (~10%).
Responsibilities
  • Adhere to Clinical Standard Operating Procedures (SOP) and Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines
  • Under guidance of manager, assist with the development, tracking and management of central Clinical Operations activities.
  • Assist with development of standard processes, tracking and documentation to facilitate efficient and high-quality Clinical Operations processes across clinical studies.
  • Assist with Clinical Operations Systems activities, such as maintenance of information in the Learning Management System (LMS), Clinical Trial Management System (CTMS), Medical Client Relationship Management (CRM) system or electronic Trial Master File (eTMF).
  • May support the selection and set up of new clinical systems (e.g., eTMF, CTMS).
  • Assist in the development, review, distribution, and archiving of study documents and reports (e.g., essential documents, plans, training materials, study guides, manuals, etc.).
  • May assist with set-up and maintenance of clinical study eTMF(s), if applicable, and work with the CRO or vendor to audit and resolve discrepancies.
  • Assist study teams with sample management, reconciliation and generate trial progress tracking system.
  • May liaise with Clinical Supply and other cross functional teams with processing shipments, returns, and assist with in-house drug, specimen, and ancillary supply reconciliation.
  • Provide support to address existing and potential gaps in the eTMF.
  • Support Clinical Operations during internal gap assessments and during inspections.
  • Support inspection readiness.
  • Track and prepare study-specific information utilizing databases, trackers, and other study tools.
  • Assist in the preparation of meeting materials, including scheduling, developing agendas, and minute-taking for internal Clinical Operations team meetings.
  • May conduct other activities to support study teams, such as gathering investigator and site information to support study start-up, maintenance, and close-out activities, contacting investigator sites to provide study specific information, working with cross-functional study teams and vendors to assist in the coordination of clinical trial activities.
  • May serve as the point of contact for vendors or study sites, study monitors for clinical supplies or document collection.
  • Support other clinical operations activities as appropriate.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?